Evidence map›Paper›PMID 32831150›Full record

ArticleRetrovirology2020

Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting: a collaborative study for performance evaluation of diagnostic assays in Japan.

Kazu Okuma, Madoka Kuramitsu, Toshihiro Niwa, Tomokuni Taniguchi, Yumiko Masaki, Gohzoh Ueda, Chieko Matsumoto, Rieko Sobata, Yasuko Sagara, Hitomi Nakamura and 30 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Retrovirology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Epidemiology and Clinical Outcomes of HTLV-1: A Comprehensive Narrative Review of Endemic and Nonendemic Regions.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. How Can We Prevent Mother-to-Child Transmission of HTLV-1?International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 20 institutions in 1 country.

Kazu OkumaDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Madoka KuramitsuDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Toshihiro NiwaResearch and Development Division, Fujirebio Inc., Tokyo, Japan.
Tomokuni TaniguchiProtein Technology, Engineering 1, Sysmex Corporation, Kobe, Japan.
Yumiko MasakiRoche Diagnostics K.K., Tokyo, Japan.
Gohzoh UedaAbbott Japan LLC, Tokyo, Japan.
Chieko MatsumotoCentral Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Rieko SobataCentral Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Yasuko SagaraDepartment of Quality, Japanese Red Cross Kyushu Block Blood Center, Fukuoka, Japan.
Hitomi NakamuraDepartment of Quality, Japanese Red Cross Kyushu Block Blood Center, Fukuoka, Japan.
Masahiro SatakeCentral Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Kiyonori MiuraDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Naoki FuchiDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hideaki MasuzakiDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Akihiko OkayamaDepartment of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
Kazumi UmekiDepartment of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
Yoshihisa YamanoDivision of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Tomoo SatoDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
Masako IwanagaDepartment of Clinical Epidemiology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kaoru UchimaruDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Makoto NakashimaDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Atae UtsunomiyaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Ryuji KubotaDivision of Neuroimmunology, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan.
Kenji IshitsukaDepartment of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan.
Hiroo HasegawaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Daisuke SasakiDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Ki-Ryang KohDepartment of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Mai TakiRakuwakai Kyoto Medical Examination Center, Kyoto, Japan.
Kisato NosakaDepartment of Hematology, Kumamoto University of Medicine, Kumamoto, Japan.
Masao OgataDepartment of Hematology, Oita University Hospital, Oita, Japan.
Isao NaruseDepartment of Infection and Immunology, SRL Inc., Tokyo, Japan.
Noriaki KanekoDepartment of Infection and Immunology, SRL Inc., Tokyo, Japan.
Sara OkajimaDepartment of Infection and Immunology, SRL Inc., Tokyo, Japan.
Kenta TezukaDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Emi IkebeDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Sahoko MatsuokaDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Kazuo ItabashiDepartment of Pediatrics, Showa University School of Medicine, Tokyo, Japan.
Shigeru SaitoDepartment of Obstetrics and Gynecology, University of Toyama, Toyama, Japan.
Toshiki WatanabeDepartment of Hematology and Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Isao HamaguchiDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan. 130hama@niid.go.jp.
National Institute of Infectious Diseases · JPNagasaki University · JPJapanese Red Cross Society, Japan · JPSRL (Japan) · JPThe University of Tokyo · JPJapanese Red Cross Fukuoka Hospital · JPKagoshima University · JPNagasaki University Hospital · JPSt. Marianna University School of Medicine · JPUniversity of Miyazaki · JPAbbott (Japan) · JPFujirebio (Japan) · JPImamura Hospital · JPKumamoto University · JPKyoto Medical Center · JPOita University Hospital · JPRoche (Japan) · JPShowa University · JPSysmex (Japan) · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe reliable diagnosis of human T-cell leukemia virus type 1 (HTLV-1) infection is important, particularly as it can be vertically transmitted by breast feeding mothers to their infants. However, current diagnosis in Japan requires a confirmatory western blot (WB) test after screening/primary testing for HTLV-1 antibodies, but this test often gives indeterminate results. Thus, this collaborative study evaluated the reliability of diagnostic assays for HTLV-1 infection, including a WB-based one, along with line immunoassay (LIA) as an alternative to WB for confirmatory testing.

resultsUsing peripheral blood samples from blood donors and pregnant women previously serologically screened and subjected to WB analysis, we analyzed the performances of 10 HTLV-1 antibody assay kits commercially available in Japan. No marked differences in the performances of eight of the screening kits were apparent. However, LIA determined most of the WB-indeterminate samples to be conclusively positive or negative (an 88.0% detection rate). When we also compared the sensitivity to HTLV-1 envelope gp21 with that of other antigens by LIA, the sensitivity to gp21 was the strongest. When we also compared the sensitivity to envelope gp46 by LIA with that of WB, LIA showed stronger sensitivity to gp46 than WB did. These findings indicate that LIA is an alternative confirmatory test to WB analysis without gp21. Therefore, we established a novel diagnostic test algorithm for HTLV-1 infection in Japan, including both the performance of a confirmatory test where LIA replaced WB on primary test-reactive samples and an additional decision based on a standardized nucleic acid detection step (polymerase chain reaction, PCR) on the confirmatory test-indeterminate samples. The final assessment of the clinical usefulness of this algorithm involved performing WB analysis, LIA, and/or PCR in parallel for confirmatory testing of known reactive samples serologically screened at clinical laboratories. Consequently, LIA followed by PCR (LIA/PCR), but neither WB/PCR nor PCR/LIA, was found to be the most reliable diagnostic algorithm.

conclusionsBecause the above results show that our novel algorithm is clinically useful, we propose that it is recommended for solving the aforementioned WB-associated reliability issues and for providing a more rapid and precise diagnosis of HTLV-1 infection.

Indexed as

AlgorithmsAntibodies, ViralBlotting, WesternDiagnostic Tests, RoutineHTLV-I AntigensHTLV-I InfectionsHumansHuman T-lymphotropic virus 1ImmunoassayJapanPolymerase Chain ReactionProvirusesReagent Kits, DiagnosticReproducibility of ResultsSensitivity and SpecificityAntibodies, ViralHTLV-I AntigensReagent Kits, DiagnosticConfirmatory testDiagnostic algorithmHTLV-1 antibodyHTLV-1 infectionLIAPCRWB

Identifiers

PMID32831150
PMCPMC7444053
OpenAlexW3080588042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.